Heterogeneous CD52 expression among hematologic neoplasms: Implications for the use of alemtuzumab (CAMPATH-1H)
Rodig, SJ; Abramson, JS; Pinkus, GS; Treon, SP; Dorfman, DM; Dong, HY; Shipp, MA; Kutok, JL
HERO ID
2454532
Reference Type
Journal Article
Year
2006
Language
English
PMID
| HERO ID | 2454532 |
|---|---|
| In Press | No |
| Year | 2006 |
| Title | Heterogeneous CD52 expression among hematologic neoplasms: Implications for the use of alemtuzumab (CAMPATH-1H) |
| Authors | Rodig, SJ; Abramson, JS; Pinkus, GS; Treon, SP; Dorfman, DM; Dong, HY; Shipp, MA; Kutok, JL |
| Journal | Clinical Cancer Research |
| Volume | 12 |
| Issue | 23 |
| Page Numbers | 7174-7179 |
| Abstract | Purpose: CD52 is a GPI-linked glycoprotein expressed by B cells, T cells, monocytes, and macrophages. The humanized monoclonal antibody alemtuzumab (CAMPATH-1H) is specific for CD52 and is Food and Drug Administration - approved for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL). The utility of CAMPATH in the treatment of other hematologic neoplasms has been explored; however, a comprehensive survey of CD52 expression among a broad spectrum of WHO-defined tumor types has not been completed. <br> <br>Experimental Design: We evaluated 294 hematologic neoplasms for the presence of CD52 using standard immunohistochemical techniques on paraffin-embedded biopsy specimens fixed with formalin, B-Plus, Zenker's acetic acid, or B5-formalin. <br> <br>Results: The vast majority of low-grade B cell lymphoproliferative disorders (CLL/small lymphocytic leukemia, follicular lymphoma, lymphoplasmacytic lymphoma, hairy cell leukemia, and mucosa-associated lymphoid tissue lymphomas) express CD52. In addition, we found that the majority of precursor B cell acute lymphoblastic leukemia/lymphomas express this antigen. In contrast, there is surprising heterogeneity in CD52 expression among more aggressive B cell lymphomas, with 25% of cases of diffuse large B cell lymphoma and Burkitt lymphoma demonstrating no detectable CD52. In addition, the majority of neoplasms of the T cell lineage are negative for the antigen, including most cases of precursor T cell acute lymphoblastic leukemia/ lymphoma, anaplastic large cell lymphoma, and peripheral T cell lymphoma, not otherwise specified. Finally, the vast majority of cases of acute myeloid leukemia, Hodgkin lymphoma, and multiple myeloma are negative for CD52 expression. <br> <br>Conclusion: In contrast with CLL, the variable expression of CD52 among other hematologic malignancies suggests that target validation on a case-by-case basis will likely be necessary to guide the rational analysis of CAMPATH therapy. |
| Doi | 10.1158/1078-0432.CCR-06-1275 |
| Pmid | 17145843 |
| Wosid | WOS:000242691000043 |
| Url | http://dx.doi.org/10.1158/1078-0432.CCR-06-1275 |
| Is Certified Translation | No |
| Dupe Override | No |
| Is Public | Yes |
| Language Text | English |